Lesson 7: Cardiovascular, Metabolic and Immune Botanicals

Interpret traditional cardiotonic and immunomodulator categories without replacing proven therapy.

Back to Course

Course 13: Botanical Medicine

Lesson 7 of 12. These notes synthesize uploaded historical botanical lectures with separately identified current safety guidance. Traditional uses are not evidence of clinical efficacy or a prescribing directive.

Cardiotonic is not a treatment licence

  • Crataegus (hawthorn) is a traditional cardiotonic; this does not justify replacing guideline-directed therapy for heart failure, hypertension or ischemic disease. Evaluate possible blood-pressure and cardiac-medication interactions.

Recognize toxic cardiotonic plants

  • Convallaria majalis and Digitalis species contain cardiotoxic glycosides and are not suitable for self-prescribing. Their therapeutic index and toxicity can be severe.

Metabolic considerations

  • Diabetes medications and botanical supplements may affect each other through absorption, metabolism or glucose effects. In a person using insulin or sulfonylureas, consider hypoglycemia and ensure glucose monitoring.

Immunomodulator versus immunostimulant

  • The course notes use Ganoderma and Lentinula as immunomodulators and Echinacea as an immunostimulant. These traditional classifications do not prove treatment or prevention of serious infection.

Immunosuppressed patients

  • Check transplant medicines, chemotherapy, autoimmune conditions, infection symptoms and vaccine advice. Never replace antimicrobial treatment or urgently indicated evaluation with “immune support.”

Applied clinical case

A transplant recipient asks to take a multi-herb “immune booster” while on tacrolimus. What is the priority?

Show model reasoning and clinical disposition

Perform full product and medication reconciliation with the transplant team or pharmacist. Potential pharmacokinetic and immune effects can compromise transplant outcomes.

Knowledge checks

  1. Why are digitalis-like plants high risk?
  2. What does “immunomodulator” mean in traditional notes?
  3. What evidence is required before claiming a clinical benefit?

Source and safety links

Downloadable study materials

Practice lesson questions